Streamlining Cigna Rexulti Prior Authorization

Understanding Cigna Rexulti Prior Authorization Requirements

Rexulti (brexpiprazole) is an atypical antipsychotic often prescribed for major depressive disorder (as adjunctive therapy) and schizophrenia. Given its therapeutic area and cost profile, Cigna Healthcare typically requires prior authorization to ensure medical necessity, appropriate use, and adherence to formulary guidelines. This process often involves clinical documentation supporting diagnosis, previous treatment trials, and patient response.

Navigating Cigna's Pharmacy and Medical Benefit Channels for Rexulti

For most Cigna Healthcare commercial and Medicare Advantage plans, Rexulti is covered under the pharmacy benefit, with prior authorization managed by Evernorth's Express Scripts. Submissions for pharmacy benefit PAs route through Express Scripts' provider PA system and are also supported via ePA partners like CoverMyMeds and Surescripts. If Rexulti were to be administered in a medical setting, the prior authorization would route through Cigna Healthcare's medical PA channel, often via the CignaforHCP.com portal or X12 278 transactions.

Key Prior Authorization Pathways for Rexulti with Cigna Healthcare

• **Pharmacy Benefit:** Primarily managed by Express Scripts, an Evernorth company, utilizing their dedicated provider PA system.
• **Electronic PA (ePA):** Available for prescriber-initiated workflows through industry partners like CoverMyMeds and Surescripts for pharmacy benefit drugs.
• **Medical Benefit:** Submissions through the CignaforHCP.com provider portal or via X12 278 transactions for facility-administered medications.
• **Policy Access:** Cigna Healthcare publishes detailed coverage policies and medical necessity guidelines on its public provider site.
• **Specialty Pharmacy Consideration:** While Rexulti is typically a retail pharmacy drug, Accredo, Evernorth's specialty pharmacy, manages PAs for complex or specialty injectables, which may apply to similar high-cost medications.

Common Denial Reasons and Appeal Pathways for Rexulti with Cigna

Denials for Rexulti prior authorizations from Cigna Healthcare often stem from insufficient clinical documentation, failure to meet step therapy requirements, or lack of demonstrated medical necessity as per Cigna's published coverage policies. Denials are typically communicated via X12 277/835 transactions or status updates on CignaforHCP.com. Klivira helps identify and address these issues proactively.

Addressing Rexulti PA Denials with Cigna Healthcare

• **Documentation Insufficiency:** Lack of clinical notes supporting diagnosis, previous treatment failures, or contraindications to preferred alternatives.
• **Step Therapy Non-Compliance:** Failure to document trials of less costly, preferred formulary alternatives.
• **Medical Necessity:** Inadequate justification for the specific indication or dosage per Cigna's clinical guidelines.
• **Appeal Process:** Cigna Healthcare provides clear appeal pathways, including peer-to-peer reviews for clinical denials, detailed on their provider portal and in the Cigna Provider Manual.
• **Expedited Appeals:** Available for urgent care situations, following specific Cigna Healthcare protocols.

Klivira's Integration with Cigna Healthcare for Rexulti PA Automation

Klivira automates the submission and tracking of Cigna Rexulti prior authorizations by integrating directly with Cigna Healthcare's administrative systems and Evernorth's Express Scripts. Our platform supports both medical and pharmacy benefit workflows, leveraging robust connectivity to CignaforHCP.com and ePA channels to streamline documentation exchange and status updates. This reduces administrative burden and accelerates approval times.